QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:EDIT

Editas Medicine (EDIT) Stock Forecast, Price & News

$6.92
-0.19 (-2.67%)
(As of 09/28/2023 ET)
Compare
Today's Range
$6.84
$7.05
50-Day Range
$6.92
$9.31
52-Week Range
$6.33
$14.23
Volume
1.21 million shs
Average Volume
1.81 million shs
Market Capitalization
$564.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.57

Editas Medicine MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
125.0% Upside
$15.57 Price Target
Short Interest
Bearish
18.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
0.29mentions of Editas Medicine in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$46,111 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.55) to ($2.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

709th out of 969 stocks

Biological Products, Except Diagnostic Industry

114th out of 161 stocks


EDIT stock logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Price History

EDIT Stock News Headlines

Are Gene Therapy Stocks The Market's Next Big Winners? (EDIT)
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
1 Gene Editing Stock to Buy Now, and 1 to Sell
Editas Medicine, Inc. (EDIT)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Cantor Fitzgerald Keeps Their Buy Rating on Editas Medicine (EDIT)
RBC Capital Sticks to Its Hold Rating for Editas Medicine (EDIT)
EDIT - Editas Medicine, Inc.
SVB Securities Sticks to Its Hold Rating for Editas Medicine (EDIT)
Robert W. Baird Remains a Buy on Editas Medicine (EDIT)
Editas Medicine Plunges After Pricing 12.5 Mln Share Offering
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings
8/02/2023
Today
9/28/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
226
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.57
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+124.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-220,430,000.00
Net Margins
-1,065.39%
Pretax Margin
-1,065.39%

Debt

Sales & Book Value

Annual Sales
$19.71 million
Book Value
$5.25 per share

Miscellaneous

Free Float
79,837,000
Market Cap
$565.70 million
Optionable
Optionable
Beta
1.79
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Gilmore O'Neill (Age 59)
    Pres, CEO & Director
    Comp: $815.37k
  • Dr. Bruce E. Eaton Ph.D. (Age 69)
    Exec. VP, CTO & Chief Bus. Officer
    Comp: $786.23k
  • Dr. Baisong Mei M.D.
    Ph.D., Sr. VP & Chief Medical Officer
  • Dr. Feng Zhang Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D. (Age 69)
    Co-Founder & Scientific Advisory Board Member
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Mr. Erick J. Lucera C.F.A. (Age 55)
    C.P.A., CFA, CPA, CFO & Exec. VP
  • Mr. Harry R. Gill III (Age 62)
    Sr. VP of Operations
  • Dr. Linda C. Burkly Ph.D.
    Exec. VP & Chief Scientific Officer













EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2023?

13 brokerages have issued 12 month price targets for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they expect the company's stock price to reach $15.57 in the next year. This suggests a possible upside of 124.7% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 at the beginning of the year. Since then, EDIT stock has decreased by 21.9% and is now trading at $6.93.
View the best growth stocks for 2023 here
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.20. The company had revenue of $2.89 million for the quarter, compared to the consensus estimate of $4.17 million. Editas Medicine had a negative trailing twelve-month return on equity of 55.14% and a negative net margin of 1,065.39%. The firm's revenue for the quarter was down 54.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.78) EPS.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.31%), State Street Corp (8.14%), Deep Track Capital LP (4.23%), Marshall Wace LLP (3.48%), Woodline Partners LP (3.37%) and Dimensional Fund Advisors LP (2.16%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Charles Albright, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $6.93.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $565.70 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.

How many employees does Editas Medicine have?

The company employs 226 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -